Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Imaging for recurrent prostate cancer.

D M Nudell1, A E Wefer, H Hricak

  • 1Department of Urology, University of California San Francisco, USA.

Radiologic Clinics of North America
|February 9, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The impact of FDG-PET/CT in the management of patients with vulvar and vaginal cancer.

Gynecologic oncology·2016
Same author

Updated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference.

European radiology·2015
Same author

Volume-based quantitative FDG PET/CT metrics and their association with optimal debulking and progression-free survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery.

European radiology·2015
Same author

Retraction note to: new horizons in genitourinary oncologic imaging.

Abdominal imaging·2015
Same author

Combined PET/MR: The Real Work Has Just Started. Summary Report of the Third International Workshop on PET/MR Imaging; February 17-21, 2014, Tübingen, Germany.

Molecular imaging and biology·2015
Same author

Volume and landmark analysis: comparison of MRI measurements obtained with an endorectal coil and with a phased-array coil.

Clinical radiology·2015
Same journal

Orbital Imaging.

Radiologic clinics of North America·2026
Same journal

Imaging, Management, and Treatment of Orbital Trauma.

Radiologic clinics of North America·2026
Same journal

Imaging Findings after Multidisciplinary Treatment for Orbital and Ocular Adnexal Cancers.

Radiologic clinics of North America·2026
Same journal

Orbital Tumors: What the Radiologist Needs to Know from the Orbital Surgeon's Perspective.

Radiologic clinics of North America·2026
Same journal

Multidisciplinary Management of Tumors of the Orbit.

Radiologic clinics of North America·2026
Same journal

Skull Base, Bone, Pituitary-Regions around Orbit that Affect Vision.

Radiologic clinics of North America·2026
See all related articles

Evaluating recurrent prostate cancer after initial treatment requires various imaging tests. These methods, combined with clinical and PSA data, help predict and monitor recurrence sites effectively.

Area of Science:

  • Oncology
  • Radiology
  • Urology

Background:

  • Prostate cancer recurrence after radical prostatectomy (RP), radiation therapy (RT), or cryosurgery presents a significant clinical challenge.
  • Accurate detection of recurrent prostate cancer is crucial for guiding subsequent treatment decisions.

Purpose of the Study:

  • To review and discuss the various imaging modalities available for evaluating recurrent prostate cancer.
  • To highlight the importance of integrating imaging findings with clinical and PSA parameters for predicting recurrence patterns.

Main Methods:

  • Review of current literature on imaging techniques for recurrent prostate cancer.
  • Discussion of the role of prostate-specific antigen (PSA) kinetics and tumor characteristics (grade, stage) in predicting recurrence.

Related Experiment Videos

  • Presentation of an algorithmic approach to patient monitoring based on primary treatment modality.

    • Main Results:

    • Multiple imaging modalities, including [list specific modalities if known, e.g., PET/CT, MRI], are available for detecting recurrent prostate cancer.
    • Clinical parameters (tumor grade, stage) and PSA characteristics are essential for predicting the likelihood and location of recurrence.
    • An integrated approach using imaging and clinical data is necessary for effective patient management.

    Conclusions:

    • Imaging plays a vital role in the surveillance and management of recurrent prostate cancer.
    • Personalized monitoring algorithms, tailored to the primary treatment, are essential for optimizing patient care.
    • Continued advancements in imaging technologies are needed to improve the detection and characterization of recurrent disease.